Therefore, these results suggest that BRD7 suppresses tumor growth and metastasis at least partially by negatively regulating the enhancer activity and expression of BIRC2 and that targeting the BRD7/BIRC2 regulatory axis is a potential strategy for the diagnosis and treatment of nasopharyngeal carcinoma. The gene discussed is BIRC2; the disease is neoplasm.